<DOC>
	<DOCNO>NCT01828970</DOCNO>
	<brief_summary>The purpose study evaluate effect basal-bolus detemir-aspart insulin regimen couple continuous glucose monitoring ( CGM ) glycemic control hemodialyzed patient diabetes</brief_summary>
	<brief_title>Pilot Study Glycemic Control Diabetic Hemodialyzed Patients</brief_title>
	<detailed_description>We conduct pilot prospective multicenter study five French center ( Strasbourg University Hospital , Strasbourg Sainte Anne Hospital , Colmar , Mulhouse , Valenciennes ) design evaluate feasibility effect 3 month treatment regimen rapid-acting insulin basal long-acting insulin analogue ( i.e. , aspart detemir , respectively ) along CGM glucose level control diabetic hemodialyzed patient . All patient admit nephrology department match inclusion criterion January 1st , 2010 , June 30th , 2012 , consecutively include study . CGM use analyze blood glucose excursion baseline 1 3 month treatment . It start first dialysis session continue next two day home ambulatory condition . The CGM continue next dialysis session . Therefore , total , CGM ( Navigator® ; Abbott , Rungis , France ) perform 54 hour , include two consecutive hemodialysis session 0 , 1 , 3 month treatment . The probe system subcutaneously insert begin first dialysis session analyze interstitial glucose , remove end second dialysis session . Due time require CGM calibration , plasma glucose level partially record first dialysis session .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>age 18 83 year diagnosis type 1 type 2 diabetes treatment insulin injection oral hypoglycemic agent HbA1c ≥ 7 % ( i.e. , 53 mmol/mol ) hemodialysis three month unstable anemia blood transfusion within two month prior begin study life expectancy le 1 year chronic inflammatory disease evolutive cancer require steroid treatment , chemotherapy , radiotherapy , program surgery noncompliant patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>83 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Continuous glucose monitoring</keyword>
	<keyword>Insulin analogue</keyword>
</DOC>